[1]许 俊.慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病并发社区获得性肺炎患者的临床对比[J].医学信息,2018,31(22):118-120.[doi:10.3969/j.issn.1006-1959.2018.22.033]
　XU Jun.Clinical Comparison of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Chronic Obstructive Pulmonary Disease Complicated with Community Acquired Pneumonia[J].Journal of Medical Information,2018,31(22):118-120.[doi:10.3969/j.issn.1006-1959.2018.22.033]
点击复制

慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病并发社区获得性肺炎患者的临床对比()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年22期
页码:
118-120
栏目:
临床研究
出版日期:
2018-11-15

文章信息/Info

Title:
Clinical Comparison of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Chronic Obstructive Pulmonary Disease Complicated with Community Acquired Pneumonia
文章编号:
1006-1959（2018）22-0118-03
作者:
许 俊
（东南大学附属中大医院溧水分院/南京市溧水区人民医院呼吸内科，江苏 南京 211200）
Author(s):
XU Jun
(Lishui Branch Hospital,Zhongda Hospital Affiliated to Southeast University/Department of Respiratory Medicine,People's Hospital of Lishui District,Nanjing 211200,Jiangsu,China)
关键词:
慢性阻塞性肺疾病; 慢性阻塞性肺疾病急性加重期; 社区获得性肺炎; 肺功能
Keywords:
Chronic obstructive pulmonary disease; Acute exacerbation of chronic obstructive pulmonary disease; Community acquired pneumonia; Pulmonary function
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2018.22.033
文献标志码:
A
摘要:
目的 探究慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病并发社区获得性肺炎患者的临床对比，旨在为临床的诊断和治疗提供科学依据。方法 选取2017年3月~2018年3月于我院接受治疗的82例COPD患者为研究对象，按照随机数表法分为两组，其中观察组42例为AECOPD患者，对照组40例为COPD合并CAP患者，比较两组患者的临床症状、肺功能以及PCT、CRP水平。结果 观察组患者呼吸困难、咳脓痰、精神差、发热等临床症状的发生率均低于对照组，差异具有统计学意义（P＜0.05）。观察组患者FEV1、FVC、FEV1/FVC分别为（64.15±7.26）ml、（62.85±7.29）ml、（62.03±5.54）%，均高于对照组的（52.51±5.75）ml、（50.85±6.74）ml、（52.34±5.61）%，差异具有统计学意义（P＜0.05）。观察组患者PCT和CRP分别为（0.52±0.07）ng/L和（21.51±1.35）mg/L，均低于对照组的（0.97±0.08）ng/L和（40.05±1.57）mg/L，差异具有统计学意义（P＜0.05）。结论 AECOPD患者与COPD合并CAP患者相比，临床症状发生情况较少，肺功能较好，对患者进行相关检测，能够提高治疗效果。
Abstract:
Objective To investigate the clinical comparison between patients with acute exacerbation of chronic obstructive pulmonary disease and patients with chronic obstructive pulmonary disease complicated with community-acquired pneumonia, aiming at providing scientific evidence for clinical diagnosis and treatment. Methods 82 patients with COPD who were treated in our hospital from March 2017 to March 2018 were enrolled in the study. They were divided into two groups according to the random number table. Among them, 42 patients in the observation group were AECOPD patients,40 patients in the control group were treated with COPD and CAP. The clinical symptoms, lung function, and PCT and CRP levels were compared between the two groups. Results The incidence of clinical symptoms such as dyspnea, cough and sputum, mental retardation and fever were lower in the observation group than in the control group, the difference was statistically significant (P<0.05). The FEV1, FVC and FEV1/FVC of the observation group were (64.15±7.26) ml, (62.85±7.29) ml, and (62.03±5.54)%, respectively, which were higher than the control group (52.51±5.75) ml, (50.85±6.74)ml, (52.34±5.61)%, the difference was statistically significant (P<0.05). The PCT and CRP of the observation group were (0.52±0.07) ng/L and (21.51±1.35) mg/L, respectively, which were lower than those of the control group (0.97±0.08) ng/L and (40.05±1.57) mg/L,the difference was statistically significant (P<0.05). Conclusion Compared with patients with COPD and CAP, AECOPD patients have fewer clinical symptoms and better lung function. Relevant tests can improve the treatment effect.

参考文献/References:


[1]房建珍,毕丽岩.慢性阻塞性肺疾病急性加重期诊治新进展[J].医学与哲学,2013,34(16):57-59.
[2]王胜,叶海勇,陈悦,等.302例慢性阻塞性肺疾病急性加重期中医证候分型[J].北京中医药大学学报,2015,38(1):57-62.
[3]张金彪,胡海涛,刘玉欣,等.改良NAP活性检测在慢性阻塞性肺疾病急性加重期诊治中的应用价值[J].山东医药,2016,56(12):65-67.
[4]廖音娟,董李晨,左美玲,等.喜炎平注射液治疗慢性阻塞性肺疾病急性加重期疗效的Meta分析[J].中国现代医学杂志,2016,26(20):102-106.
[5]石建邦,吴健卫,徐非洲,等.慢性阻塞性肺疾病急性加重期患者血清降钙素原检测的临床意义[J].中国老年学杂志,2017,37(5):1178-1180.
[6]王业亚,刘琨,李泽,等.地塞米松辅助治疗慢性阻塞性肺疾病并发社区获得性肺炎的回顾性分析[J].临床内科杂志,2016,33(1):40-42.
[7]黄书明,王永莉.COPD急性加重期与COPD合并社区获得性肺炎的对比分析[J].国际呼吸杂志,2017,37(21):1618-1622.
[8]曾小云,李慧,胡春林,等.老年人反复发生社区获得性肺炎的临床特征和危险因素分析[J].中华全科医师杂志,2016,15(6):434-438.
[9]贺筱彬,林小华,刘舜莉,等.我院2013-2015年慢性阻塞性肺疾病急性加重期抗菌药物利用评价[J].中国药房,2017,28(5):599-601,602.
[10]宁学聪,王志华.慢性阻塞性肺疾病急性加重期合并肺性脑病患者BiPAP治疗失败的危险因素分析[J].广东医学,2016,37(23):3575-3577.
[11]孙淑芬.综合加强护理病房老年慢性阻塞性肺疾病急性加重期死亡因素分析[J].中国老年学杂志,2016,36(5):1139-1141.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(22):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]吴君华,吴友茹,李 丹.血清降钙素原在AECOPD抗感染治疗中的应用价值研究[J].医学信息,2018,31(02):74.[doi:10.3969/j.issn.1006-1959.2018.02.025]
　WU Jun-hua,WU You-ru,LI Dan.Study on the Application Value of Serum Calcitonin in the Anti Infection Treatment of AECOPD[J].Journal of Medical Information,2018,31(22):74.[doi:10.3969/j.issn.1006-1959.2018.02.025]
[3]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(22):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[4]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(22):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[5]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(22):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[6]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[7]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(22):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[8]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(22):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[9]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(22):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[10]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(22):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]

更新日期/Last Update: 2018-12-03